(Q34537724)

2 August 2017

1 reference

title

Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal (English)

1 reference

2 August 2017

0 references

0 references

1 reference

2

Sake J De Vlas

1 reference

2 August 2017

Anthony Danso-Appiah

1

1 reference

2 August 2017

publication date

1 March 2002

1 reference

2 August 2017

published in

Trends in Parasitology

1 reference

2 August 2017

volume

18

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

125-129

1 reference

Use of praziquantel against schistosomiasis: a review of current status.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity seven months after treatment with praziquantel.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty-three months after treatment with praziquantel

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Chemotherapy of schistosomiasis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Efficacy of praziquantel against Schistosoma mansoni in northern Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

The epidemiology of a recent focus of mixed Schistosoma haematobium and Schistosoma mansoni infections around the 'Lac de Guiers' in the Senegal River Basin, Senegal

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Increase of intestinal schistosomiasis after praziquantel treatment in a Schistosoma haematobium and Schistosoma mansoni mixed focus

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Schistosome resistance to praziquantel: Fact or artifact?

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Schistosoma mansoni: chemotherapy of infections of different ages

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Schistosoma mansoni: Reduced efficacy of chemotherapy in infected T-cell-deprived mice

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Egg count variability and sensitivity of a thin smear technique for the diagnosis of Schistosoma mansoni.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Underestimation of Schistosoma mansoni prevalences.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

A field trial using praziquantel (BiltricideR) to treat Schistosoma mansoni and Schistosoma haematobium infection in Gezira, Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Field trials of praziquantel and oxamniquine for the treatment of schistosomiasis mansoni in Burundi.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Efficacy and tolerance of praziquantel in patients with Schistosoma mansoni infection and Symmers' fibrosis: a field study in the Sudan.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

A quantitative analysis of the diagnostic value of diethylcarbamazine provocation in endemic Wuchereria bancrofti infection

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Repeated community-based chemotherapy for the control of Schistosoma mansoni: effect of screening and selective treatment on prevalences and intensities of infection

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

A model for variations in single and repeated egg counts in schistosoma mansoni infections

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Drug resistance in human helminths: current situation and lessons from livestock

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Praziquantel: is there real resistance and are there alternatives?

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902209-7

7 January 2021

10.1016/S1471-4922(01)02209-7

Identifiers

DOI

1 reference

2 August 2017

1 reference